171. Praveen Malhotra Tells Us Why Dealing With Vendors is a Huge Part of Life Sciences IT

You've Been Heard

Philip Howard

Tech News, Technology, Business, Management, News

0.0 • 0 Ratings

🗓️ 15 September 2022

⏱️ 50 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

Praveen Malhotra Praveen Malhotra is the Vice President of Information Technology at TCR2 Therapeutics Inc. He has amassed over 20 years of experience transforming information technology in life sciences and the technology industries. Praveen also served in increasing roles of responsibility focused on enterprise platforms, applications, and global business applications at GlaxoSmithKline (formerly Tesaro Therapeutics), Endurance International Group, Aspen Technologies, and Moster Worldwide. He received an M.S. in Computer Science from New Mexico State University and a B.Tech in Mechanical Engineering from C.R. State Engineering, India. Praveen Malhotra Tells Us Why Dealing With Vendors is a Huge Part of Life Sciences IT Praveen starts by talking about determining which vendors are useful to scientists at TCR2. Later, he discusses what makes digital transformation unique in the life sciences industry, what it takes to support treatment creation and what he sees coming in the future for technology in the space.

Transcript

Click on a timestamp to play from that location

0:00.0	Hey, everyone.
0:10.0	Scott Smester here with CIO Mastermind.
0:13.5	You know who I am.
0:15.0	Check out CIO Mastermind.com.
0:18.0	If you need support, coaching, training, be more effective in your C-suite position.
0:24.8	We're here today talking to Praveen Mahaltra.
0:30.4	Did I say that?
0:31.4	Did I say your last name right?
0:33.6	That is perfect.
0:34.8	I think doing better than that.
0:39.3	I'm nailing it today, everyone. And he's with a company called TCR Squared Therapeutics, Inc.
0:44.3	Tell us a little bit about that.
0:46.3	Sure. So first of all, I'm super excited to be on the podcast today.
0:52.3	Excellent.
0:53.3	And from our company perspective, again, we are TCR squared.
1:00.3	The name itself comes from the fact that we are actually working on a T-cell receptor,
1:10.7	which is an antigen which which takes care of a solid tumor
1:15.1	if the direction is accurate in terms of how we use it.
1:20.1	So we have two products in the clinic right now.
1:24.1	The first one is in phase two, and that is actually targeting solid tumors,
1:32.6	specifically in the mesothelin, and there are several other indications where we are trying to progress
1:41.9	this particular drug.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Philip Howard, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Philip Howard and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.